Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2016-02-03 Regulatory Filings
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-02-03 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to Form S-1 on Form S-3 registration statement filed with the SEC. It includes detailed information about securities registration, share issuances, resale of shares, and amendments to previous registration statements. The content is regulatory in nature, related to capital raising and securities registration, but it is not a financial report, earnings release, or management discussion. It is a formal filing related to capital structure and securities offerings. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length is substantial and contains detailed registration and offering information, confirming it is not a mere announcement or certification but a substantive filing about capital changes.
2016-01-25 English
FORM 10-K
Annual Report FY 2015
2015-12-22 English
PRIMARY DOCUMENT
Director's Dealing
2015-10-30 English
PRIMARY DOCUMENT
Director's Dealing
2015-10-29 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 2, 2015, by ITUS Corporation. The key content is the announcement of entering into a material definitive agreement for an At Market Issuance Sales Agreement to sell up to $10 million of common stock. This is a clear update on the company's capital raising activities and financing arrangements. There are no financial statements or detailed financial performance data included, only the description of the financing agreement and related filing. According to the filing definitions, this fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about the financing agreement, so it is not a mere announcement of a report or a regulatory filing fallback. Therefore, the classification is CAP with high confidence.
2015-10-02 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.